Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 27, 2023

SELL
$0.64 - $3.15 $8,465 - $41,665
-13,227 Reduced 4.97%
253,113 $178,000
Q4 2022

Jan 27, 2023

SELL
$2.03 - $4.28 $6,089 - $12,840
-3,000 Reduced 1.11%
266,340 $602,000
Q3 2022

Oct 28, 2022

SELL
$3.04 - $5.14 $5,350 - $9,046
-1,760 Reduced 0.65%
269,340 $862,000
Q4 2021

Jan 24, 2022

BUY
$10.83 - $18.41 $507,580 - $862,839
46,868 Added 20.9%
271,100 $3.66 Million
Q3 2021

Oct 25, 2021

BUY
$13.07 - $18.84 $131,118 - $189,002
10,032 Added 4.68%
224,232 $4.03 Million
Q1 2021

Apr 22, 2021

BUY
$16.56 - $25.46 $1,655 - $2,546
100 Added 0.05%
214,200 $4.28 Million
Q4 2019

Jan 24, 2020

SELL
$15.87 - $23.12 $172,459 - $251,245
-10,867 Reduced 4.83%
214,100 $4.62 Million
Q3 2019

Oct 24, 2019

BUY
$16.91 - $36.27 $1,014 - $2,176
60 Added 0.03%
224,967 $4.1 Million
Q2 2019

Jul 18, 2019

BUY
$31.0 - $36.3 $403 - $471
13 Added 0.01%
224,907 $8 Million
Q1 2019

May 07, 2019

BUY
$31.58 - $46.35 $1,989 - $2,920
63 Added 0.03%
224,894 $7.56 Million
Q4 2018

Jan 28, 2019

BUY
$30.43 - $56.65 $1,156 - $2,152
38 Added 0.02%
224,831 $7.39 Million
Q3 2018

Nov 02, 2018

SELL
$46.46 - $68.49 $111,318 - $164,102
-2,396 Reduced 1.05%
224,793 $13.7 Million
Q2 2018

Aug 01, 2018

SELL
$46.25 - $104.45 $346,320 - $782,121
-7,488 Reduced 3.19%
227,189 $11.1 Million
Q1 2018

May 01, 2018

SELL
$57.4 - $108.44 $2.89 Million - $5.46 Million
-50,323 Reduced 17.66%
234,677 $24.9 Million
Q4 2017

Feb 12, 2018

BUY
$23.02 - $60.5 $639,403 - $1.68 Million
27,776 Added 10.8%
285,000 $17 Million
Q3 2017

Oct 30, 2017

BUY
$17.79 - $24.0 $7,116 - $9,600
400 Added 0.16%
257,224 $6.17 Million
Q2 2017

Aug 11, 2017

BUY
N/A
256,824
256,824 $5.02 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track New York State Teachers Retirement System Portfolio

Follow New York State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on New York State Teachers Retirement System with notifications on news.